相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study
Yi-Long Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Koji Haratani et al.
BMC MEDICINE (2020)
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients
J. Rogado et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade
Tomoki Sakakida et al.
ONCOLOGY LETTERS (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
Naoto Okada et al.
CLINICAL THERAPEUTICS (2019)
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study
Yoshihiko Tomita et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2018)
Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study
Toyoaki Hida et al.
CLINICAL LUNG CANCER (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
Yukihiro Toi et al.
ONCOLOGIST (2018)
An Update on Immunotherapy for Solid Tumors: A Review
Toan Pham et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Association of pre-existing thyroid autoimmunity with the development of thyroid dysfunction induced by nivolumab.
Shiro Kimbara et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C. Iyer et al.
THYROID (2018)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
Jessica C. Hassel et al.
CANCER TREATMENT REVIEWS (2017)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
分享论文
